Catalog Number: LTA-V010-1MG
Name: SARS-CoV-2 Spike RBD Monoclonal Antibody
Immunogens: Utilizes 2019 novel Coronavirus spike protein receptor binding domain as the immunogens for monoclonal antibody production
Antibody Subtype: IgG1
Concentration: 1mg, 0.4mg/ml, Lyophilized in Phosphate Buffered Saline, pH7.4, (10mg in stock, Call for Price)
Advantages: Chemically synthesized peptides were oxidized to form the correct disulfide bridge. The peptides were folded in a proprietary folding solution to maintain the native protein structure
Progress Update: ELISA to be tested, Hybridoma cell fusion to be performed, Heavy/Light chains to be sequenced, Genes to be constructed, Proteins to be expressed in a mammalian cell lines, Antibodies to be tested and characterized.
ELISA Results: Coating Antigens: SARS-CoV-2 Spike RBD;
Coating Concentration: 2 ug/ml, 100ul / well; Coating Buffer: Phosphate Buffered Saline, pH7.4;
Secondary Antibody: Goat Anti-Mouse IgG (H+L), HRP Conjugated;
Western Blot: Western Blots against SARS-CoV-2 S1 Protein and S2 Protein (Negative Control).
Antibody Binding to Trimers: Antibodies were captured to the surface of SARS-CoV-2 S Trimer Proteins
Antibody Binding to RBD Protein: Antibodies can bind to immobilized SARS-CoV-2 RBD 6His tagged protein tightly.